CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology ... data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American ...

A POWERFUL NEW technique for editing genomes, CRISPR-Cas9, is the latest in a series of advances in biotechnology that ... primary moral goal for today’s bioethics can be summarized in a single ...

MAIA Biotechnology, Inc. (NYSE American ... efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 Annual Meeting of the American Society of ...

The Biotechnology Program has also expanded its STEM outreach efforts to include a summer internship program for high school ...

PanGIA Biotech, a company advancing urine-based ... biopsy (Abstract #3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly Targeted ...

Our faculty, staff, and students actively disseminate their work through diverse channels, reaching a wide array of audiences. They publish in prestigious academic journals, industry publications, and ...

PanGIA Biotech, a company advancing urine-based, AI-driven diagnostics for early cancer detection, today announced that an abstract co-authored by researchers from PanGIA Biotech, Entopsis Inc ...

April 30, 2025--(BUSINESS WIRE)--PanGIA Biotech, a company advancing urine ... 3080), has been accepted for presentation in the poster session titled Developmental Therapeutics—Molecularly ...

The Work-Around for the White House’s Missing Transcripts JD Vance Is Right — AI Is a Threat to Your Children, Not Your Job Trump Wins a Big One at the Supreme Court for Executive ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...

With rising global cancer rates necessitating new forms of diagnosis and treatment, Hong Kong-based biotech startup Phase Scientific International announced Tuesday it raised $34 million in a ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech ...